Lavofloxacin lactate
Based on 34 publication(s) in Google Scholar
Lavofloxacin lactate ((-)-ofloxacin lactate) is a class of broad-spectrum antimicrobials that can kill or inhibit a variety of bacteria. Lavofloxacin lactate binds to DNA rotase and topoisomerase IV, resulting in blocked DNA replication and repair, thus inhibiting bacterial growth. Lavofloxacin lactate can be used to study resistance mechanisms in bacteria, including studying resistance genes and mutations.
For research use only. We do not sell to patients.
- CAS No.: 294662-18-3
- Formula: C21H26FN3O7
- Molecular Weight:451.45
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Lavofloxacin lactate
More- Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]
- Nat Commun. 2025 May 10;16(1):4366. [Abstract]
- Acta Pharm Sin B. 2025 Dec;15(12):6382-6398. [Abstract]
- Chem Eng J. 2026 Feb 12.
- J Exp Med. 2026 Mar 2;223(3):e20241287. [Abstract]
- EBioMedicine. 2025 Jul:117:105776. [Abstract]
- Food Res Int. 2026 Aug 31:238:119421. [Abstract]
- Clin Chem. 2019 Dec;65(12):1522-1531. [Abstract]
- Virulence. 2026 Dec 31;17(1):2646808. [Abstract]
- Commun Biol. 2025 Oct 6;8(1):1425. [Abstract]
- Results Chem. 2024 Oct.
- Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
- Antibiotics (Basel). 2022 Feb 1;11(2):192. [Abstract]
- Int J Antimicrob Agents. 2025 Oct;66(4):107551. [Abstract]
- PLoS Pathog. 2026 Jan 26;22(1):e1013903. [Abstract]
- Toxics. 2025 Feb 5;13(2):122. [Abstract]
- ACS Infect Dis. 2024 Apr 12;10(4):1327-1338. [Abstract]
- Antimicrob Agents Chemother. 2021 Feb 17;65(3):e01921-20. [Abstract]
- Microbiol Spectr. 2025 Oct 15:e0122125. [Abstract]
- Microbiol Spectr. 2025 Jul;13(7):e0307424. [Abstract]
- AMB Express. 2024 Dec 24;14(1):141. [Abstract]
- Water. 2025 Jun 6.
- Infect Drug Resist. 2026 May 8;19.
- Eur J Clin Microbiol Infect Dis. 2025 Sep 29. [Abstract]
- Infect Genet Evol. 2025 Sep:133:105780. [Abstract]
- PLoS One. 2024 Apr 18;19(4):e0298577. [Abstract]
- Future Microbiol. 2025 Oct 13:1-10. [Abstract]
- Chin J Traumatol. 2024 Sep;27(5):295-304. [Abstract]
- Diagn Microbiol Infect Dis. 2026 Feb;114(2):117181. [Abstract]
- Res Sq. 2026 Mar 9.
- SSRN. 2025 Oct 14.
- Res Sq. 2025 Aug 05.
- bioRxiv. 2025 January 19.
- bioRxiv. 2024 May 10.
-
Microbiological Assay
-
Microbiological Assay
-
Cell Proliferation/Viability Assay
-
Microbiological Assay
-
Microbiological Assay
All DNA/RNA Synthesis Isoforms
More
Biological Activity
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 294662-18-3
-
Molecular Weight 451.45
-
Formula C21H26FN3O7
-
SMILES
O=C(C(C1=O)=CN2[C@@H](C)COC3=C(N4CCN(C)CC4)C(F)=CC1=C23)O.CC(O)C(O)=O
-
Synonyms
(-)-Ofloxacin lactate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (34)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]2025 Dec 15;10(1):406. PMID: 41392286 -
Nat Commun
Phenotypic drug susceptibility testing for Mycobacterium tuberculosis variant bovis BCG in 12 hours. [Abstract]2025 May 10;16(1):4366. PMID: 40348759
Lavofloxacin lactate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 May 10;16(1):4366. [Abstract]
M. bovis BCG Russia WT in LFX (0-25 h) 1 mg/L.
Lavofloxacin lactate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 May 10;16(1):4366. [Abstract]
M. bovisBCG Russia FQR in LFX (0-25 h) 1 mg/L.
-
Acta Pharm Sin B
2025 Dec;15(12):6382-6398. PMID: 41477334
Lavofloxacin lactate purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2025 Dec;15(12):6382-6398. [Abstract]
Levofloxacin exhibited toxicity at 25 × Cmax, which resulted in a 65% reduction in organoid cell viability.
-
-
J Exp Med
2026 Mar 2;223(3):e20241287. PMID: 41400657 -
EBioMedicine
Diverse impacts of different rpoB mutations on the anti-tuberculosis efficacy of capreomycin. [Abstract]2025 Jul:117:105776. PMID: 40449326
Lavofloxacin lactate purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2025 Jul:117:105776. [Abstract]
Killing curves of different Ms rpoB mutants after exposure to LFX (0-48 h) at 1 μg/mL (5 × MIC) in 7H9 medium.
-
Food Res Int
Prevalence, plasmid transmission, and chromosomal integration of blaCTX-M genes in Salmonella isolated from retail chicken and pork meats in China. [Abstract]2026 Aug 31:238:119421. PMID: 42215089 -
Clin Chem
Discovering Cross-Reactivity in Urine Drug Screening Immunoassays through Large-Scale Analysis of Electronic Health Records. [Abstract]2019 Dec;65(12):1522-1531. PMID: 31578215 -
Virulence
Antibacterial efficacy and mechanism of the novel antimicrobial peptide lachnospirin-1 against Acinetobacter baumannii. [Abstract]2026 Dec 31;17(1):2646808. PMID: 41838520 -
Commun Biol
The acetyltransferase CysE modulates virulence and drug resistance of Mycobacterium tuberculosis by interfering with oxidative stress responses. [Abstract]2025 Oct 6;8(1):1425. PMID: 41053365 -
-
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
Antibiotics (Basel)
Antibacterial Activity of the Novel Drug Gepotidacin against Stenotrophomonas maltophilia-An In Vitro and In Vivo Study. [Abstract]2022 Feb 1;11(2):192. PMID: 35203795
Lavofloxacin lactate purchased from MedChemExpress. Usage Cited in: Antibiotics (Basel). 2022 Feb 1;11(2):192. [Abstract]
Determined minimum inhibitory concentrations (MICs) of Gepotidacin, Levofloxacin, Moxifloxacin, and Co-trimoxazole against S. maltophilia.
-
Int J Antimicrob Agents
Elucidating adaptive compensatory tigecycline resistance mechanisms of RamA, RarA and SoxS in Klebsiella pneumoniae. [Abstract]2025 Oct;66(4):107551. PMID: 40499596 -
PLoS Pathog
Anti-orthopoxvirus drugs inhibit lumpy skin disease virus replication by targeting viral DNA polymerase. [Abstract]2026 Jan 26;22(1):e1013903. PMID: 41587213 -
Toxics
2025 Feb 5;13(2):122. PMID: 39997937 -
ACS Infect Dis
Lusutrombopag as a Repurposing Drug in Combination with Aminoglycosides against Vancomycin-Resistant Enterococcus. [Abstract]2024 Apr 12;10(4):1327-1338. PMID: 38567846 -
Antimicrob Agents Chemother
Dihydrotanshinone I Is Effective against Drug-Resistant Helicobacter pylori In Vitro and In Vivo. [Abstract]2021 Feb 17;65(3):e01921-20. PMID: 33318002 -
Microbiol Spectr
Montelukast treats Streptococcus pneumoniae-induced sepsis via antibacterial and anti-inflammatory activities. [Abstract]2025 Oct 15:e0122125. PMID: 41090944 -
Microbiol Spectr
Antimicrobial resistance of rapidly growing mycobacteria isolated from companion animals in Taiwan. [Abstract]2025 Jul;13(7):e0307424. PMID: 40387379 -
AMB Express
Repurposing pinaverium bromide against Staphylococcus and its biofilms with new mechanisms. [Abstract]2024 Dec 24;14(1):141. PMID: 39718732 -
-
-
Eur J Clin Microbiol Infect Dis
Evaluation of EUCAST rapid antimicrobial susceptibility testing (RAST) for carbapenemase-producing Klebsiella pneumoniae with focus on KPC variants. [Abstract]2025 Sep 29. PMID: 41023358 -
Infect Genet Evol
Polymyxin B combined with amikacin delays the resistance of Klebsiella pneumoniae to polymyxin B by modulating the expression of NlpE. [Abstract]2025 Sep:133:105780. PMID: 40480594 -
PLoS One
In vitro activity of ceftazidime/avibactam, cefiderocol, meropenem/vaborbactam and imipenem/relebactam against clinical strains of the Stenotrophomonas maltophilia complex. [Abstract]2024 Apr 18;19(4):e0298577. PMID: 38635685 -
Future Microbiol
2025 Oct 13:1-10. PMID: 41082411 -
Chin J Traumatol
The cytochrome P4501A1 (CYP1A1) inhibitor bergamottin enhances host tolerance to multidrug-resistant Vibrio vulnificus infection. [Abstract]2024 Sep;27(5):295-304. PMID: 38981821 -
Diagn Microbiol Infect Dis
2026 Feb;114(2):117181. PMID: 41205476 -
-
-
-
-
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)